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Membrane transporters are critical modulators of
drug pharmacokinetics, efficacy, and safety. One
example is the proton-dependent oligopeptide
transporter PepT1, also known as SLC15A1, which
is responsible for the uptake of the b-lactam antibi-
otics and various peptide-based prodrugs. In this
study, we modeled the binding of various peptides
to a bacterial homolog, PepTSt, and evaluated a
range of computational methods for predicting the
free energy of binding. Our results show that a hybrid
approach (endpoint methods to classify peptides
into good and poor binders and a theoretically exact
method for refinement) is able to accurately predict
affinities, which we validated using proteoliposome
transport assays. Applying the method to a homol-
ogy model of PepT1 suggests that the approach re-
quires a high-quality structure to be accurate. Our
study provides a blueprint for extending these
computational methodologies to other pharmaceuti-
cally important transporter families.
INTRODUCTION
The application of computational chemistry in drug development
has centered for a long time around indirect ligand-based tech-
niques, such as pharmacophoremodeling and 3D-QSAR studies
(Caporuscio and Tafi, 2011). Recently, the emergence of X-ray
crystal structures of pharmaceutically important membrane pro-
teins has shifted the paradigm toward direct structure-based ap-
proaches, for example, computing the free energy of binding of
relevant ligands to a protein, and thereby finding or optimizing
lead compounds. Scoring functions are currently the method
of choice due to their cheap computational cost (Chen and Shoi-
chet, 2009; Schlessinger et al., 2011; Geier et al., 2013). While
this method can work for screening a large library of compounds
to produce an initial list of candidates, more robust techniques
are needed for accurately predicting binding, such as for ranking
ligands, especially for highly dynamic proteins like membrane
transporters.
Understanding how a drug candidate interacts with membrane
transporters is becoming an important step in drug development
(Giacomini et al., 2010). Compelling clinical evidence indicatesCell Chemicthat membrane transporters expressed in the epithelia of the in-
testine, kidney, and liver, and in the endothelia of the blood-brain
barrier influence not only drug absorption and distribution (Dob-
son and Kell, 2008) but also their therapeutic efficacy and poten-
tial adverse reactions (Shitara and Sugiyama, 2002; Cusatis et al.,
2006). A recent update of the U.S. Food and Drug Administration
guidelines includes extensive recommendations on in vitro and
in vivo studies of transporter-mediated drug-drug interactions
(U.S. Department of Health and Human Services et al., 2012).
Most of the key transporters that have been characterized belong
to two major superfamilies: ATP-binding cassette transporters
and solute carriers (SLCs). Of particular interest to this paper is
the well-studied and pharmacologically important proton-depen-
dent oligopeptide transporters (POT) family member, PepT1, also
known as solute carrier family 15 member 1 (SLC15A1), which is
the key representative of clinically important SLC transporters
involved in drug transport.
PepT1 is expressed predominantly in the intestinal epithelia
(Fei et al., 1994; Shen et al., 1999) and plays a crucial role in
maintaining nitrogen homeostasis by coupling the uptake of di-
peptides and tripeptides to the proton electrochemical gradient
(Daniel and Spanier, 2006). Based on the 20 naturally occurring
amino acids, there are more than 8,000 possible peptides that
could be its substrates, most of which are expected to be trans-
ported (Ito et al., 2013). PepT1, therefore, has a highly promiscu-
ous binding site that can accommodate a wide range of ligands
with diverse structures and chemistries. In addition to nutritional
peptides, it is well established that PepT1 also recognizes and
transports a range of drug compounds, such as many b-lactam
antibiotics (Luckner and Brandsch, 2005) and the tumor sup-
pressor bestatin (Inui et al., 1992). The promiscuity of this trans-
porter has been exploited in the development of prodrugs such
as the antiviral acyclovir (Ganapathy et al., 1998) and the anti-
hypotensive drug midodrine (Tsuda et al., 2006). In both cases,
an amino acid residue was attached to the active drug moiety
via an esterification reaction, leading to a compound that is
transported across the lining of the gut by PepT1, thereby
increasing its oral bioavailability. Understanding how ligands
interact with these transporters and being able to predict their
affinity could, therefore, enable the rational design of drugs
with better pharmacokinetics (Brandsch et al., 2008).
Structurally, PepT1 belongs to themajor facilitator superfamily
(Pao et al., 1998) and so consists of 12 core transmembrane he-
lices divided into N- and C-terminal bundles, with two additional
helices observed in the bacterial homologs (Newstead, 2011;
Solcan et al., 2012; Doki et al., 2013; Guettou et al., 2013;
Zhao et al., 2014; Boggavarapu et al., 2015). The binding site isal Biology 23, 299–309, February 18, 2016 ª2016 The Authors 299
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B Figure 1. Modeling the Binding of Peptides
Based on the Crystal Complexes of PepTSt
(A) Superposition of the two binding modes of
peptides to PepTSt. The dipeptide AlaPhe (orange)
binds in a horizontal orientation (PDB: 4D2C),
whereas the tripeptide triAla (purple) binds in a
vertical orientation (PDB: 4D2D) (Lyons et al.,
2014). For clarity, transmembrane helices H2, H11,
HA, and HB are removed.
(B) Surface representation of the binding pocket of
PepTSt with the positions of key interacting resi-
dues outlined.
(C) Models of six dipeptides bound to PepTSt.
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side of the membrane as per the alternating access mechanism
(Radestock and Forrest, 2011), with distinct helices controlling
this process in a cooperative scissor-like motion (Fowler et al.,
2015). The bacterial isoforms share a high sequence identity
with mammalian PepT1 within the peptide-binding site, suggest-
ing there may be universally conserved binding and transport
mechanisms (Newstead, 2014). Recent high-resolution struc-
tures of a homolog from Streptococcus thermophilus, PepTSt,
demonstrated that there are at least two binding orientations
within this cavity: the dipeptide AlaPhe (PDB: 4D2C) adopted a
horizontal pose with respect to the plane of the membrane,
whereas the tripeptide AlaAlaAla (triAla, PDB: 4D2D) bound verti-
cally (Lyons et al., 2014), consistent with the dual proton:peptide
stoichiometry observed for this transporter (Parker et al., 2014).
A second, lower-resolution study resolved the structures of two
tripepides (AlaAlaAla, PDB: 4TPJ, and brominated AlaTyrAla,
PDB: 4TPG) and a dipeptide (brominated AlaTyr, PDB: 4TPH)
when bound to PepTSo2 (Guettou et al., 2014). For this protein,
all three peptides bound in the same horizontal posewith respect
to themembrane. These studies have provided essential insights
into the molecular basis of promiscuity by the POT transporters,
but also raise a further question of how the numerous other di-
and tripeptides and, more importantly, drugs interact?
In this article, we develop a computational approach for accu-
rately predicting the affinities of ligands to the peptide trans-
porters. We modeled the binding of various dipeptides based
on the crystal structure of the PepTSt-AlaPhe complex, and
used a range of in silico free energymethods to predict their bind-
ing affinities. All thesemethods are very well established and have
been applied to a wide range of protein-ligand systems (Chodera
et al., 2011).Wefind that themoderately cheap endpointmethods
provide a fast way to classify these ligands into good and poor
binders. Our results suggest PepTSt generally prefers neutral
over charged substrates. Applying a more rigorous theoretical
method to a series of dipeptides reveals the importance of the
N-terminal side chain in determining the overall affinity. Using a
proton-driven competition uptake assay, we validated these pre-300 Cell Chemical Biology 23, 299–309, February 18, 2016 ª2016 The Authorsdictions but found discrepancies with
basic dipeptides. We suggest that these
dipeptides bind in a vertical orientation,
similar to the previously observed triAla
PepTSt complex, to accommodate their
large side chains. Applying the methodto a homologymodel of humanPepT1 suggests that the accuracy
of this method depends on the quality of the available protein
structure. Nevertheless, our results help to explain how the pro-
drug approach hasworked for PepT1 by revealing the importance
of the N- and C-terminal interactions in the binding site. Overall,
this study demonstrates how in silico methodologies can work
in tandemwith in vitro assays to predict ligand affinities in a phar-
maceutically relevant membrane transporter.
RESULTS
Endpoint and Exact Free Energy Methods Accurately
Predict Affinities
To determine which computational methods can best predict the
binding of di- and tripeptides to PepTSt, we needed a test set of
peptides and a selection of computational methods to validate.
For the test set, we chose seven dipeptides and one tripeptide
(triAla) for which experimental transport data were available.
Crystal structures of one dipeptide (AlaPhe) and one tripeptide
(triAla) bound to PepTSt are known (PDB: 4D2C, 4D2D, respec-
tively; Lyons et al., 2014). The pose of the other six dipeptides
was assumed to be the same as AlaPhe, as illustrated in Figure 1.
We then selected a range of computational methods for calcu-
lating binding free energies which we would validate using the
test set. The methods can be categorized based on the amount
of computational resource each requires (Figure 2D); at the low
end is the structure-based scoring function found in AutoDock
Vina (Trott and Olson, 2010). Next we chose three different
endpoint methods: the linear interaction energy (LIE; Aqvist
et al., 1994), molecular mechanics generalized Born surface
area (MMGBSA; Onufriev et al., 2000), andmolecular mechanics
Poisson Boltzmann surface area (MMPBSA; Kollman et al.,
2000). All of these require some molecular dynamics (MD) simu-
lation and hence are more expensive. Finally, we selected a
theoretically exact method, thermodynamic integration (TI; Kirk-
wood, 1935) to calculate differences in binding free energies
(DDG) to refine the other predictions. Experimental binding
data for PepTSt, and POT transporters in general remain scarce,
AB
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Figure 2. Endpoint and Exact Free Energy
Methods can Predict Affinities Accurately
(A–C) PredictedDG from free energy methods: (A)
scoring functions (fast method), (B) endpoint
methods (intermediate methods), and (C) theo-
retically exact method (slow method), compared
with IC50 values from transport assay. The mag-
nitudes of DG obtained from endpoint methods
are significantly larger than expected due to
the absence of an entropic term in the calcula-
tion. Spearman’s correlation coefficient, r, was
calculated to measure the ability of each method
to reproduce the same ranking as experimental
data. Y error bars indicate statistical errors from
de-correlated and equilibrated DG data during
MD simulations, while X error bars indicate the
standard deviations from triplicate experiments.
(D) The performance of all prediction methods
and the computational cost based on a quad
core processor. AutoDock does not require any
simulation and each docking protocol takes
around30s, and therefore isplottedas102CPUh.
Standard one-letter code abbreviations have
been used for all di- and tri-peptides.
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competition transport assays and measure the half maximal
inhibitory concentration (IC50) values (Solcan et al., 2012). Unlike
certain enzymes, however, transporters have more complicated
kinetics such that the relationship between IC50 and DG is un-
clear (Eraly, 2008). We therefore compared these two datasets
in a qualitative manner using Spearman’s correlation coefficient
(Lehmann and D’Abrera, 1998), r, which assesses the ability of
each computational approach to reproduce the ranking of sub-
strates based on experimental IC50 values.
Since it does not require anyMD simulations, the scoring func-
tion is the fastest method to estimate binding affinities. Our re-
sults with AutoDock (Figure 2A), however, shows that it is also
the least accurate (r = 0.43). This is not surprising as AutoDock
uses a simplified scoring function (Wang et al., 2002). Although
not tested in this study, it is possible that other scoring functions
may produce better predictions for peptide transporters as no
single docking program performs best across all protein families
(Warren et al., 2006; Ross et al., 2013). Also, AutoDock does not
account for the conformational sampling of the ligand and the
residues in the binding site of the protein as it uses only one
snapshot of the protein-ligand complex for its calculation. It is
worth noting that this may be improved by using multiple con-
formers of the complex, for example from MD simulations, as
has been done with several other membrane transporters
(Schlessinger et al., 2011; Geier et al., 2013). As the binding of
the peptide test set was modeled using the same structure,Cell Chemical Biology 23, 299–309, FAutoDock Vina predicted that they all
have very similar DG values. For each
dipeptide, the range of DG values pre-
dicted for the nine poses generated is
small (0.5 kcal/mol), although the score
for the pose most similar to the crystal
structure or homology model is not al-
ways the highest (Figure S1). We there-fore conclude that AutoDock Vina does not accurately predict
peptide-binding affinities for PepTSt.
Encouragingly, all three endpoint free energy methods
managed to rank the peptide test set well (Figure 2B) compared
with the experimental data (rz 0.7). The predictedDGvalues for
the eight peptides span a wider range, allowing us to better
distinguish the subset of well-transported peptides (PhePhe,
AlaPhe, AlaAla, and AlaTyr) from poorly transported peptides
(triAla and GluGlu). We assume that this increase in accuracy
is primarily a result of using an ensemble of conformations
generated during the MD simulation, which accounts for the
conformational sampling of the ligand and the protein. As
endpoint methods require only simulations of the bound and
unbound states, the computational cost required for each calcu-
lation is relatively modest and therefore they are suitable candi-
dates for a high-throughput workflow to differentiate between
high-from low-affinity peptides.
Upon closer examination, however, we found that the
endpoint methods poorly ranked peptides with similar IC50
values, for example the r value of the MMPBSA methods for hy-
drophobic dipeptides with IC50 % 100 mM is 0.0, i.e., random
(Figure S2). We hypothesized that the more rigorous method,
TI might improve the ranking of AlaPhe, AlaAla, AlaTyr, and
PhePhe by calculating the change in DG (DDG) when the amino
acids in AlaAla were mutated into either Phe or Tyr. These values
were subsequently added to the results of the endpoint
methods. We found that by implementing this step, wemanagedebruary 18, 2016 ª2016 The Authors 301
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Figure 3. Further Predictions Suggest that
the N-Terminal Side Chain Contributes
More Toward the Binding of a Dipeptide
than the C Terminus
(A)DG values for all 400 dipeptides as predicted by
the LIE method, arranged according to the overall
chemical property of the peptide. Solid lines indi-
cate the average of DG for each category and the
dotted line represents the overall mean DG value.
The magnitudes of DG for all peptides were pre-
dicted to be above zero due to the lack of entropic
term in the calculation.
(B) DG values plotted in pair, each for two di-
peptides made of the same residues but in
different orders, e.g., GluMet and MetGlu. The line
drawn on the graph represents perfect linear cor-
relation.
(C) The TI method was used to calculate DDG of
alchemically changing the side chain of either the N
or C terminus of AlaAla into Phe, Asp, Glu, or Lys.
Errors were calculated by dividing all simulations
into an equal number of independent bins as indi-
cated by the reverse cumulative averaging method
(Yang et al., 2004).
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experimental ranking (r = 1.0) (Figure 2C). It is acknowledged,
however, that due to the few data points, the apparently higher
correlation to experimental data may be artificial.
To quantify and compare the exact amount of resources
required for each prediction method, computational usage in
hours of single CPU usage (CPUh) was estimated based on
the performance of GROMACS for MD simulation using an Intel
quad core Xeon processor (Figure 2D). It is no surprise that
the more computational input fed into the methods, the more
accurate the predictions become. The endpoint methods are
an excellent compromise between good performance and
low cost. We therefore conclude that it is most efficient to
adopt a hybrid approach: using endpoint methods to broadly
classify the ligands into high- and low-affinity substrates and
then applying TI where necessary to further refine specific
predictions.
Binding of Dipeptides Sensitive to their N-Terminal
Residue
Having determined, using the test set of peptides, which free
energy methods are most accurate, we now make some predic-
tions for the bacterial transporter PepTSt and test them experi-
mentally. Since the LIE method ranked the test set the best,
we used it to predictDG for all possible 400 dipeptides.We again
assumed that all dipeptides bind in the same orientation as
AlaPhe, as has been elucidated by Lyons et al. (2014). In agree-302 Cell Chemical Biology 23, 299–309, February 18, 2016 ª2016 The Authorsment with previous studies on PepT1 (Vig
et al., 2006), PepT2 (Biegel et al., 2006),
and a peptide transporter from Saccharo-
myces cerevisiae, Ptr2p (Ito et al., 2013),
our results predict that neutral dipeptides
made of hydrophobic and polar amino
acids are the preferred substrates for
PepTSt with almost all binding free en-ergies below average (Figure 3A). As expected, we also found
that acidic dipeptides bind least well with the lowest affinities
predicted if both side chains are negatively charged, e.g.,
AspGlu. However, our results suggest that dipeptides with basic
residues have moderate affinities for PepTSt, while an experi-
mental transport assay showed that LysLys has a high IC50
value, indicating poor transport (Solcan et al., 2012).
Previous modeling of PepT1 suggested that the binding site
predominantly recognizes the peptide backbone and therefore
substrate affinities should not be significantly affected by the
sequence of residues (Foley et al., 2010). To check if our results
agreed with this prediction, we replotted each DG value against
its sequence-reversed equivalent, i.e., Ala-X versus X-Ala (Fig-
ures 3B and S3). If order does not matter, then the points should
all fall on a straight line; however, we found a relatively low cor-
relation (r2 = 0.32) with some pairs differing significantly, for
example, AlaLys and LysAla. Our results therefore suggest that
the order of amino acid residues does influence the overall affin-
ity in PepTSt.
To explore this further, TI calculations were performed to
determine how the binding free energy changes when the N-
or C-terminal side chain of AlaAla is transmuted into either
phenylalanine, aspartate, glutamate, or lysine (Figure 3C). Nega-
tive DDG values (and therefore better binding) were obtained
when either side chain was substituted with Phe, exemplifying
the inclination of this transporter toward hydrophobic peptides
as shown by other POTs (Gebauer and Hartrodt, 2003; Biegel
A B
C
( ) ( )
Figure 4. Proton-Driven Competition Up-
take Assays
(A) IC50 competition curves for AlaAsp and AspAla
showing residual uptake of 3H-AlaAla in a proteo-
liposome-based transport assay.
(B) Similar IC50 competition curves for AlaLys,
LysAla, and triAla.
(C) Apparent ‘‘DDG’’ values derived based on the
ratio of IC50 of Ala-X and X-Ala, compared with the
corresponding calculated DDG values from simu-
lation.
Errors were calculated as per Figure 3.
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into a charged residue, however, resulted in a reduction of
binding affinity (positive DDG), in agreement with our LIE predic-
tions. In all cases, when the N terminus was altered, the
magnitude of the change in binding affinity was larger than the
identical change at the C terminus. These results indicate that
the N-terminal residue is crucial in determining the selectivity
of PepTSt.
We then investigated which residues in the binding site of the
transporter interact with the side chains of the dipeptides (Fig-
ure S4). The C-terminal side chain mainly occupies a hydropho-
bic pocket and forms hydrophobic interactions primarily with
Tyr68 and Trp296. The N-terminal side chain, however, con-
tacts a group of polar residues including Tyr30, Asn156, and
Asn328. All of these residues have been previously shown to
be important for peptide transport by PepTSt (Solcan et al.,
2012). These analyses suggest that the N-terminal side chain
potentially binds more strongly to the binding site via multiple
electrostatic interactions and hydrogen bonds, and thereby is
more sensitive to changes, whereas the C-terminal counterpart
is accommodated inside a hydrophobic pocket that can adapt
to various chemical groups without a large energetic penalty,
and therefore is less sensitive when perturbed to another side
chain.
To test these predictions, we performed proton-driven
competition uptake assays for AlaAsp, AspAla, AlaLys, and
LysAla using radiolabeled AlaAla as the reporter substrate. The
results were then compared with the uptake of the neutral
peptides, AlaAla and triAla (Figures 4A and 4B). To make com-
parison with our in silico predictions easier, we determined the
ratio of IC50 values between AspAla and AlaAsp as well as be-
tween LysAla and AlaLys, and calculated the apparent ‘‘DDG’’
values (Figure 4C). Consistent with our in silico predictions, hav-
ing the aspartate residue at the N terminus is more detrimental
to transport compared with having the same residue at the C ter-
minus, as exemplified by the larger IC50 of AspAla (300 mM)Cell Chemical Biology 23, 299–309, February 18, 2016 ª2016 The Authors 303.
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tcompared with AlaAsp (100 mM) and
therefore the negative apparent ‘‘DDG’’
value. A similar experiment for positively
charged dipeptides, AlaLys and LysAla,
however, showed the opposite trend. Ly-
sAla has a lower IC50 than AlaLys, i.e.,
150 mM and 2.1 mM, respectively, and
their apparent ‘‘DDG’’ value is therefore
positive. This indicates that for lysine,positioning this residue on the C terminus of a dipeptide is
more detrimental to its affinity.
Lysine-Containing Dipeptides are Predicted to Bind in a
Tripeptide-like Pose
The discrepancy between our computational predictions and
experimental data for positively charged dipeptides could be
as a result of many different factors such as inadequate sampling
and force field errors. One other possible reason is that these
peptides do not bind in the same horizontal pose as AlaPhe
As the vertical pose is the only alternative binding mode
observed in crystal structures (Figure 1B), we explored this hy-
pothesis by modeling the binding of AlaAla, AlaLys, and LysAla
based on the crystal structure of PepTSt bound to triAla (PDB
4D2D; Lyons et al., 2014). TriAla has three residues, so there
are two possible ways of modeling a dipeptide: (1) removing
the C-terminal residue and using the first and second residues
as the template or (2) removing the N-terminal residue and using
the second and third residues as the template. The forme
approach positions the model dipeptide closer to the cyto-
plasmic side, and henceforth is called the bottom model
whereas the latter places the peptide nearer to the extracellula
side (top model) (Figure 5A). As before, we performed TI to
alchemically convert either the N- or C-terminal side chain o
AlaAla in this vertical binding modes into lysine, and subse-
quently calculated how the difference in binding free energy
(DDG) between LysAla and AlaLys.
Our results for both the bottom and top models suggest tha
AlaLys has a less negative DG value and thereby binds less
tightly compared with LysAla, as suggested by the positive
DDG (Figure 5B), in agreement with previously performed trans-
port assays. Further inspection of the alternative binding models
suggests that the strong binding of LysAla stems from favorable
salt bridges formed via the ε-amino group with Tyr68 and Glu300
in the bottommodel (Figure S5A) or Asn156 in the topmodel (Fig-
ure S5B). In contrast, the lysine side chain of AlaLys protrudes
A B Figure 5. Re-Modelling the Binding of
LysAla and AlaLys Based on a Tripeptide,
triAla
(A) Two ways to model the binding of a dipeptide
based on triAla: (1) by removing the C-terminal
residue, and using the first and second residues as
template (bottom models) and (2) by removing the
N-terminal residue, and using the second and third
residues as template (top). The figures overlay the
new models of AlaLys and LysAla (orange stick
representation) on top of triAla (purple).
(B) The TI method was used to calculate DDG of
alchemically transforming the N- or C-terminal side
chain of AlaAla (in both bottom and top models)
into lysine. These are compared with the apparent
‘‘DDG’’ values derived based on the ratio of IC50 of
AlaLys and LysAla from the transport assays.
Errors were calculated as per Figure 3.
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While our modeling appears to suggest that two possible verti-
cal binding sites exist for a dipeptide, i.e., the bottom and top
models, we acknowledge that in reality this might not be the
case. The binding of triAla to PepTSt in the original crystal struc-
ture showed fewer contacts with residues in the binding cavity
compared with AlaPhe, indicating a weak interaction, consistent
with the higher IC50 value (Lyons et al., 2014). Similarly, in our
simulation, a ligand bound in this orientation was able to move
up and down, suggesting that there are no distinct ‘‘bottom’’
and ‘‘top’’ binding sites, instead there is just one large vertical
cavity. Hence, one would expect to obtain similar values of
DDG for both models. That this is not the case suggests the TI
simulations have not converged, which is not surprising given
the likely timescale for the ligand to explore the vertical pocket.
Despite this, as they both show the same trend as experiment,
our current results suggest thatAlaLysandLysAlabind in a similar
orientation to triAla, rather than the horizontal pose of AlaPhe.
Nevertheless, further high-resolution crystal structures are still
required to verify the validity of our prediction for these peptides.
Experimental Structures are Essential for Accurate
Predictions
A primary goal of this study is to develop a transferable approach
of relevance to drug discovery. We therefore tried our method on
a homology model of the pharmaceutically relevant human
PepT1 (Beale et al., 2015) and expanded the test set to include
14 drug compounds that are known substrates of this trans-
porter. Peptides were assumed to bind to PepT1 in the same
way as to PepTSt. The binding of drugs was modeled based
on the conformations of either AlaPhe or triAla according to
their size. Our predicted DG values were then compared with
the IC50 data from whole-cell transport assays (Biegel et al.,
2005; Vig et al., 2006). Unfortunately, all methods failed to distin-304 Cell Chemical Biology 23, 299–309, February 18, 2016 ª2016 The Authorsguish between good and poor binders
with correlation coefficients of 0.0 (indi-
cating that the predictions are random)
(Figure S6).One potential reason for this loss of predictive ability is the lack
of a high-resolution crystal structure of human PepT1. To inves-
tigate how much the approach depends on the quality of the
protein structure, a series of homology models for the bacterial
homolog PepTSt were built using as templates, in decreasing
order of quality: (1) the crystal structure of PepTSt itself (PDB:
4D2C and 4D2D), (2) the crystal structure of GkPOT (PDB:
4IKV) that shares 50% sequence identity with PepTSt, and (3)
the crystal structure of LacY (PDB: 1PV6), which has only
25% sequence homology compared with PepTSt. For the
same peptide test set as before, all three homology models
showed lower correlations for all methods compared with pre-
dictions using the crystal structure of PepTSt. Interestingly, the
predictive ability of all the endpoint methods degrades propor-
tionally to the quality of the protein structure (Figure 6), with the
best model showing a slight decrease in the r value, followed
by larger decreases for the intermediate and poor-quality
models. Taken together, these results suggest that, while our
current approach can be applied to other members of the pep-
tide transporter family, a high-resolution crystal or electron mi-
croscopy structure is essential to achieve accurate results.
DISCUSSION
We have demonstrated that computational modeling, molecular
simulation, and free energy calculations can accurately predict
protein-ligand interactions for a membrane transporter. Using
an endpoint method, LIE, we first classified all 400 possible
dipeptide ligands into strong and weak binders. In agreement
with experimental data from other peptide transporters (Vig
et al., 2006; Biegel et al., 2006; Ito et al., 2013), we found that un-
charged peptides are, on average, the best substrates, while
acidic residues bind weakly. Refining these results using a
theoretically rigorousmethod, TI, we then found that theN-termi-
nal residue of a dipeptide contributes significantly toward
selectivity. These predictions were tested experimentally, which
Figure 6. Comparison of Performance of Binding Affinity Predic-
tions Using a Scoring Function (AutoDock) and Endpoint Methods,
LIE, MMGBSA, and MMPBSA, for Homology Models of PepTSt as
Marked with Asterisks
The template used for each model is shown in parentheses. The number in
each box represents Spearman’s correlation coefficient, r, between predicted
DG and experimental IC50 data for a test set of eight peptides (as shown in
Figure 2). These are colored from white (0.0) to blue (1.0).
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ing the basic peptides based on the vertical binding orientation
restored agreement between simulation and experiment, there-
fore we hypothesize that these basic dipeptides may not interact
with PepTSt in the canonical dipeptide-binding pose, but instead
possibly mimic a tripeptide.
It is important at this stage to highlight the limitations of our
computational approach. The MD simulations were performed
using a molecular mechanics force field, which is a classical
approximation of a more complex quantum mechanical reality
at the atomic level. It is well established, however, that this force
field is accurate at reproducingmany experimental results (Shirts
et al., 2003). Themagnitude of the absoluteDG values calculated
by the endpoint methods are large and mostly positive, rather
than small and negative as one would expect (Figures 2B and
3A). This is due to various assumptions we have made. The
MMGBSA andMMPBSAmethods neglect the entropic contribu-
tions, DS, from the protein and ligand, although we expect the
change in entropy to be similar since all of the ligands are
structurally similar (Oehme et al., 2012). In principle, one could
estimate the change in entropy; however, the currently available
methods are not precise and return very large standard errors
(Kar et al., 2011). For the LIE method, we implemented
hydroxyl-based scaling factors (Hansson et al., 1998) for
simplicity, instead of the more sophisticated parametrizations
that take into account other chemical groups (Wang et al.,
1999; Almlof et al., 2007). While these computed DG values
should not be considered as the true binding free energy, they
give meaningful results when used qualitatively, for example, in
the comparison between various ligands to understand the gen-
eral trend of binding affinity. Our modeling is also limited to the
inward open conformation, so the DG calculated might not be
representative for other conformations of the transporter.
Despite these limitations, our predictions for PepTSt using the
peptide test set show good agreement with experimental data,
suggesting that these methods are indeed sufficient to study
ligand interactions.
A ligand-based substrate template of PepT1 (Bailey et al.,
2000) suggested that dipeptides are better substrates than tri-Cell Chemicpeptides. However, this template fails to account for the gener-
ally poor transport behavior of basic dipeptides that show worse
affinities than neutral tripeptides (Eddy et al., 1995; Terada et al.,
2000). Here, we propose based on computer modeling and
competition assays that the lower affinities of these dipeptides
arise from a different binding pose. Unlike neutral and acidic di-
peptides, a dipeptide with lysine residues is proposed to bind
like a tripeptide in a vertical binding orientation, which results
in poorer transport as this binding mode is less tightly coordi-
nated (Lyons et al., 2014). The large extended lysine side chain
makes the total length of AlaLys and LysAla 10 A˚, which is
about the same as the backbone of a tripeptide. As such,
positioning these dipeptides laterally like AlaPhe may cause un-
favorable steric clashes and the only way for them to bind is by
treating their large side chain effectively as an additional residue.
As the side chain of an arginine residue is of similar length and is
also capped by a positive charge, we conjecture that dipeptides
with arginine may also interact this way, which would explain
their poor uptake.
The importance of the N terminus for peptide binding to PepT1
has been demonstrated by previous studies (Borner et al., 1998;
Meredith et al., 2000), which suggested that the amino group is
responsible for aligning the rest of the molecule in the central
binding cavity. Similar results were observed for Ptr2p (Ito
et al., 2013), where the N-terminal residue showed a higher pro-
pensity toward determining whether a substrate belongs to a
high- or low-affinity group. Our studies lend further support to
this idea by showing that the side chain on the N terminus is
the primary determinant of binding selectivity in PepTSt. The
structural reasoning behind this observation is that this side
chain contacts a group of polar residues in the binding site via
multiple electrostatic interactions, while the C-terminal side
chain is surrounded by an electro-neutral binding cavity. As
PepTSt and human PepT1 share 80% sequence identity within
the peptide-binding site, it is likely that PepT1 has a similar
substrate recognition mechanism. This would explain why the
peptide prodrug approach targeting PepT1 has been very suc-
cessful. These prodrugs are structurally analogous to a dipep-
tide, and the added amino acid acts as a pseudo N terminus
and the active drug moiety the C terminus (Figure 7). While the
N-terminal amino acid is crucial to gain affinity to the transporter,
the drug compound itself fits well inside the large hydrophobic
cavity, and hence the prodrugs are recognized and transported
by PepT1. This prodrug recipe has been employed for various
drugs such as the antivirals valacyclovir (Ganapathy et al.,
1998), valganciclovir (Sugawara et al., 2000), and cidofovir
(McKenna et al., 2005).
Generating a substrate-binding model for a membrane trans-
porter presents enormous possibilities for rational drug design.
Previous studies of the mammalian PepT1 transporter pro-
duced a simplified two-dimensional model (Meredith et al.,
2000), followed later by three-dimensional pharmacophores
(Biegel et al., 2005; Vig et al., 2006; Foley et al., 2010; Pedretti
et al., 2008). A more detailed structure-based model is
imperative following the recent crystallographic and thermody-
namic evidence that this transporter operates with at least
two distinct binding modes (Parker et al., 2014). We made
the best use of these data by combining various computational
techniques alongside experimental transport assays to suggestal Biology 23, 299–309, February 18, 2016 ª2016 The Authors 305
A C
B
Figure 7. A Model of Peptide Prodrug Bind-
ing to PepT1
(A) Structural comparison of an antiviral prodrug
valacyclovir and AlaPhe suggests that the
attached amino acid, valine (red), acts as a pseudo
N terminus, whereas the active drug, acyclovir
(blue), mimics the position of the second residue of
a dipeptide.
(B) Surface representation of the binding site of
PepTSt-AlaPhe (crystal structure) and PepT1-
valacyclovir (homology model) highlighting the
position of the phenylalanine side chain and
acyclovir inside a hydrophobic cavity, depicted by
dotted circles.
(C) Other prodrugs that target PepT1 following the
approach of adding an amino acid residue to form
an N terminus.
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While it is currently not possible to directly apply our methods
to the human PepT1 due to the lack of a high-resolution
crystal structure, our promising results with its model system,
PepTSt, demonstrate its potential for the study of drug-trans-
porter interactions. With the ever-increasing computational
power and available crystal structures of membrane trans-
porters, we expect this approach to be extended to other rele-
vant transport systems and larger compound libraries in the
near future.SIGNIFICANCE
When a drug is taken orally, it has to pass through the lining
of the gut to enter the blood circulation and reach its target.
Membrane proteins found in the gut epithelium, for example,
the human peptide transporter, PepT1, play key roles in
mediating the absorption of orally prescribed drugs.
Designing drugs that can strongly bind to PepT1 will there-
fore improve bioavailability, and in turn optimize dosing
and minimize undesirable side effects. Here, we demon-
strate an accurate way to computationally determine how
well a ligand binds to a bacterial homolog of PepT1. This
approach is capable of discriminating strong and weak
binders and elucidating the origin of ligand selectivity in
this transporter, which we then validate using in vitro trans-
port assays. Studying drug-transporter interactions is
becoming an important component of rational drug design.
We foresee that this method will be more widely employed
in the future to study other medically relevant membrane
transporter families.306 Cell Chemical Biology 23, 299–309, February 18, 2016 ª2016 The AuthorsEXPERIMENTAL PROCEDURES
The binding of both peptides and drugs was
modeled based on the structure of PepTSt-AlaPhe
(PDB: 4D2C) and PepTSt-triAla (PDB: 4D2D) com-
plexes (Lyons et al., 2014). For predicting the bind-
ing free energy, DG, using a scoring function
(AutoDock Vina; Trott and Olson, 2010), each pep-
tide and drug compound was docked to the bind-
ing site of the protein and the affinity score from the
pose most similar to the crystal structure (forAlaPhe and triAla) or model (for other ligands) was taken as the DG value.
For DG predictions using the endpoint methods, 1-ns MD simulations were
performed using GROMACS 4.5.4 (Hess et al., 2008) with parameters ex-
plained in detail in the Supplemental Information. We performed two simula-
tions for the LIE method: (1) a protein-ligand complex in membrane and (2)
the ligand in bulk solution. The GROMACS tool, g_lie, was used to compute
DG values with the a scaling constant set to 0.18 (Luzhkov and Aqvist, 2001;
Osterberg and Aqvist, 2005) and the b scaling constant set to either 0.5,
0.43, 0.37, or 0.33 based on the number of hydroxyl groups on the ligandmole-
cule (Hansson et al., 1998). For MMGBSA and MMPBSA, the single trajectory
protocol was used (Hou et al., 2011), where only the simulation of protein-
ligand complex was run and the trajectories of unbound protein and free ligand
were extracted from it. The calculation of DGwas done using the MMPBSA.py
program (Miller et al., 2012) with the implicit solvation parameters (saltcon and
istrng) set to 0.15 M.
For predictions of DDG by the TI method, alchemical MD simulations were
performed using either the PepTSt-AlaPhe crystal complex or PepTSt-AlaAla
model for the starting coordinates. The dual topology approach was employed
where both the vanishing and growing atoms were represented separately. All
transformations involved only the non-bonded interactions, while bonded
interactions were kept the same throughout the simulations (Boresch and
Karplus, 1999; Boresch, 2002). Two set of MD simulations were run: (1) the
transformation of peptide ligand bound to PepTSt (bound state) and (2) the
transformation of peptide ligand in bulk solution (unbound state). The transfor-
mation of both states was divided into three steps: (1) removing the partial
charges of the disappearing chemical groups, (2) removing the van de Waals
interactions of the disappearing groups while adding that of the emerging
groups, and (3) adding the partial charges of the emerging groups. A soft
core potential (Beutler et al., 1994) was applied in step (2) to avoid singularities
and instabilities. These transformations were coupled to a scaling parameter,
l, where at l = 0, the non-bonded terms of the initial peptide were used,
while at l = 1, the non-bonded terms of the final peptide were used. Eleven
independent 5-ns MD simulations were performed at l = 0, 0.1, 0.2, 0.3, 0.4,
0.5, 0.6, 0.7, 0.8, 0.9, 1. The trapezoid rule was used to integrate the vU/vl
values to obtain DG. In the transformations with a change in the charge of
the ligand, the one-box approach described by Rashid et al. (2013) was
employed.
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rank correlation coefficient (Lehmann and D’Abrera, 1998) using the following
equation:
r= 1 6
P ðxi  yiÞ2
nðn2  1Þ ;
where xi is the ranking for experimental IC50 values, yi is the ranking for pre-
dictedDG values and n is the size of the dataset. To validate our computational
predictions, proteoliposome-based competition transport assays were per-
formed as described in Solcan et al. (2012).
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